Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO - 04/04/19
Doi : 10.1016/j.jaci.2018.11.032
Nicola A. Hanania, MB BS, MS a, Bradley E. Chipps, MD b, Noelle M. Griffin, PhD c, ∗, Bongin Yoo, PhD d, Ahmar Iqbal, MB BS, MBA d 
, Thomas B. Casale, MD e
, Thomas B. Casale, MD e a Airways Clinical Research Center, Baylor College of Medicine, Houston, Tex
b Capital Allergy and Respiratory Disease Center, Sacramento, Calif
c Aimmune Therapeutics, Brisbane, Calif
d Genentech, Inc, South San Francisco, Calif
e University of South Florida, Tampa, Fla
| This study (clinicaltrials.gov identifier: NCT01922037) was funded by Genentech, Inc, a member of the Roche Group, and Novartis Pharma AG. Benjamin L. Trzaskoma, MS, of Genentech, Inc, provided statistical analysis support. Third-party writing assistance was provided by Nicole Tom, PhD, and Mark Snape, MB BS, CMPP, of Envision Pharma Ltd, and funded by Genentech, Inc, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. |
|
| Qualified researchers may request access to individual patient-level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (our_commitment_to_data_sharing.htm). |
|
| Disclosure of potential conflict of interest: N. A. Hanania has received consultancy fees from Genentech, Novartis, GlaxoSmithKline (GSK), Boehringer Ingelheim, Teva, Sanofi/Regeneron, and Astra Zeneca. B. E. Chipps has been an advisor for, received consultancy fees from, and been a Speakers Bureau member for AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, and Teva. A. Iqbal is employee of Genentech, Inc, and owns stock in GSK and Pfizer. B. Yoo is an employee of Genentech, Inc. N. M. Griffin is an employee of Aimmune and a former employee of Genentech, Inc. T. B. Casale's university employer has received grants and consulting fees from Genentech, Inc, and Novartis. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 4
P. 1629 - avril 2019 Retour au numéro
Article précédent
- STAT1 gain-of-function compromises skin host defense in the context of IFN-? signaling
- Hanna Niehues, Berenice Rösler, Danique A. van der Krieken, Ivonne M.J.J. van Vlijmen-Willems, Diana Rodijk-Olthuis, Malou Peppelman, Joost Schalkwijk, Ellen H.J. van den Bogaard, Patrick L.J.M. Zeeuwen, Frank L. van de Veerdonk
- Large-scale, multiethnic genome-wide association study identifies novel loci contributing to asthma susceptibility in adults
- Amber Dahlin, Joanne E. Sordillo, John Ziniti, Carlos Iribarren, Meng Lu, Scott T. Weiss, Kelan G. Tantisira, Quan Lu, Mengyuan Kan, Blanca E. Himes, Eric Jorgenson, Ann Chen Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?